SpriveApp | $7,300,000 | (May 1, 2025)
Near Space Labs | $20,000,000 | (Apr 30, 2025)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
Growers Edge | $25,000,000 | (Apr 30, 2025)
Utilidata | $60,300,000 | (Apr 30, 2025)
Blooming Health | $26,000,000 | (Apr 30, 2025)
KiwiPay | $10,000,000 | (Apr 30, 2025)
VSORA | $46,000,000 | (Apr 30, 2025)
Villa | $40,000,000 | (Apr 30, 2025)
Dex | $3,100,000 | (Apr 30, 2025)
Basil Systems | $11,500,000 | (Apr 30, 2025)
eeden | $20,451,420 | (Apr 30, 2025)